Alex Carchidi

Key Points Walgreens Boots Alliance investors may experience another positive catalyst soon. It won't solve the company's underperformance. It's a risky time to buy this stock.

Key Points Weight-loss stocks are advancing stridently right now. Zealand Pharma's licensing-based business model protects it from some risks. Eli Lilly's huge manufacturing footprint and vast research output are hard to beat. 10 stocks we like better than Zealand Pharma A/s

Key Points Despite recent headwinds, Pfizer is likely to gain value over the long term. Its stock also pays a dividend, and with a high forward yield at the moment. The veteran drugmaker's current market valuation is quite appealing, too. Motley Fool Issues Rare “All In” Buy Alert

Key Points Teladoc Health has a couple of big decisions to make in the next few years. It could double down on its vertical integration efforts in the care chain. Alternatively, it could refocus on the efficiency of its most important segments.

Key Points The pharma giant continues to spend a lot of cash on important capital investments. Lilly's also spending a lot on clinical trials that could have big revenue implications. The stock trades at a hefty premium. Motley Fool Issues Rare “All In” Buy Alert

In This Article TDOC Teladoc Health (NYSE: TDOC) hasn't been an easy stock for investors to hold -- its shares are down by a shocking 88% over the last three years.

Key Points Regulators just gave a gift to one of CRISPR Therapeutics' programs. The program can now progress through the development process faster. Still, it doesn't guarantee that the program will be a success. Motley Fool Issues Rare “All In” Buy Alert

Key Points Merck just closed a deal to develop a weight-loss drug. The market appears to think Viking Therapeutics is threatened by that data. There's little reason to write off Viking here. Motley Fool Issues Rare “All In” Buy Alert

Key Points Merck just licensed a weight-loss drug candidate. There's reason to believe that the candidate could have a big edge. But, success is not guaranteed, and the program will take years to develop. Motley Fool Issues Rare “All In” Buy Alert

Key Points Pfizer reiterated its forecast for 2024 and issued a new one for 2025. Management generally tried to calm some worries from rattled shareholders. There are still a couple of issues to be aware of. 10 stocks we like better than Pfizer